Hunter Associates Investment Management LLC Has $4.03 Million Holdings in Pfizer Inc. (NYSE:PFE)

Hunter Associates Investment Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,001 shares of the biopharmaceutical company’s stock after selling 2,063 shares during the period. Hunter Associates Investment Management LLC’s holdings in Pfizer were worth $4,032,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its position in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new position in shares of Pfizer during the 4th quarter worth about $255,000. Brookstone Capital Management increased its holdings in shares of Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares during the period. ETF Store Inc. increased its holdings in shares of Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares during the period. Finally, KLCM Advisors Inc. increased its holdings in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Read Our Latest Analysis on Pfizer

Pfizer Price Performance

Shares of Pfizer stock opened at $26.00 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $147.23 billion, a price-to-earnings ratio of 72.22, a P/E/G ratio of 1.17 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The firm’s 50-day moving average price is $27.11 and its two-hundred day moving average price is $28.65.

Pfizer (NYSE:PFEGet Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.